## Krishna Institute of Medical Sciences Limited (KIMS) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Krishna Institute of Medical Sciences Limited (KIMS) operates in the Hospital industry.  It's listed on the NSE (National Stock Exchange of India) since June 28, 2021.  While specific market share data isn't provided, the company's presence in the Healthcare Services sector suggests a competitive landscape.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹593.55        |                                                                      |
| Percentage Change (PChange) | -0.29%         | Slight decrease from the previous close.                             |
| Pre-Open Activity          | ₹590.05        | Opened lower than the previous day's close.                         |
| Week High                   | ₹634.65        | Indicates recent upward price momentum.                              |
| Week Low                    | ₹350           | Significant price fluctuation within the week.                       |
| VWAP                        | ₹594.19        | Volume Weighted Average Price is close to the current price.          |
| Sector PE                   | 65.4           | Industry average Price-to-Earnings ratio.                           |
| Symbol PE                   | 65.4           | KIMS's Price-to-Earnings ratio, indicating valuation relative to earnings.|
| Delivery Percentage         | 67.79%         | Relatively high delivery percentage suggests some degree of conviction.|
| Market Depth                | Low             | Order book data shows low market depth, indicating potential volatility.|


**3. Financial Performance:**

The provided financial data shows a consistent profit after tax (PAT) and earnings per share (EPS) over the last five quarters. However, the data is unaudited for the most recent quarters.  A detailed analysis requires audited figures for a complete picture.

| Quarter      | Revenue (₹)     | Expenses (₹)    | PAT (₹)         | EPS (₹)       |
|--------------|-----------------|-----------------|-----------------|----------------|
| Q2 FY25 (U)  | 36,990          | 27,080          | 7,220           | 1.8            |
| Q1 FY25 (U)  | 33,270          | 25,110          | 6,070           | 7.58           |
| Q4 FY24 (A)  | 30,874.4        | 24,127.6        | 4,819.4         | 6.02           |
| Q3 FY24 (U)  | 30,629          | 22,858.3        | 5,835.5         | 7.29           |
| Q2 FY24 (U)  | 31,981.3        | 23,079.4        | 6,615.9         | 8.27           |

**(U) - Unaudited, (A) - Audited**

**Key Financial Ratios:**  Further analysis requires more detailed financial statements to calculate key ratios like Return on Equity (ROE), Debt-to-Equity ratio, etc.


**4. Corporate Actions and Announcements:**

* **Face Value Split:** A face value split from ₹10 to ₹2 per share occurred on September 13, 2024 (Ex-date and Record date). This increases liquidity but doesn't inherently change the company's value.
* **Analysts' Meets/Con Calls:** Several recent announcements indicate frequent interactions with analysts and institutional investors, suggesting transparency and investor relations focus.
* **Acquisition:**  An acquisition was announced on December 5, 2024.  Further details are needed to assess its impact.
* **Personnel Changes:** Changes in directors and key personnel were announced on November 29, 2024.  The impact needs further investigation.


**5. Shareholding Patterns:**

| Quarter      | Promoter & Promoter Group (%) | Public (%) | Employee Trusts (%) | Total (%) |
|--------------|-----------------------------|-------------|--------------------|-----------|
| 30-Sep-2023  | 38.84                        | 61.16       | 0.00              | 100.00    |
| 31-Dec-2023  | 38.82                        | 61.18       | 0.00              | 100.00    |
| 31-Mar-2024  | 38.82                        | 61.18       | 0.00              | 100.00    |
| 30-Jun-2024  | 38.82                        | 61.18       | 0.00              | 100.00    |
| 30-Sep-2024  | 38.82                        | 61.18       | 0.00              | 100.00    |

Promoter shareholding remains relatively stable.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The low market depth further amplifies this risk.  The provided annualized volatility (30.19%) confirms this high-risk profile.


**7. Advantages of Buying the Stock:**

* Consistent profitability (based on available data).
* Relatively high delivery percentage.
* Active investor relations.


**8. Disadvantages and Risks:**

* High volatility and low market depth.
* Reliance on unaudited financial data for recent quarters.
* Impact of recent acquisition and personnel changes is uncertain.


**9. Investment Horizon Recommendations:**

* **Short-Term (less than 3 months): Hold.** The recent price drop and low market depth suggest caution.  Waiting for more clarity on recent announcements is advisable.
* **Medium-Term (3 to 12 months): Hold.**  The company's financial performance needs further evaluation with audited figures.  The impact of the acquisition and other corporate actions needs to be assessed.
* **Long-Term (1 year and beyond): Hold/Consider Buy (with caution).**  If the company continues to demonstrate consistent financial performance and the acquisition proves beneficial, it could be a long-term investment opportunity. However, the high volatility remains a significant risk factor.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 6.5**

* Financial Health: 7/10 (Based on available data, showing consistent profitability, but needs audited figures)
* Market Performance: 6/10 (Moderate price fluctuations, high volatility)
* Volatility and Risk: 4/10 (High volatility and low market depth are significant risks)
* Corporate Actions & Governance: 8/10 (Positive signs of transparency, but impact of recent actions needs assessment)
* Shareholding Patterns: 7/10 (Stable promoter holding)

**Analysis Score (out of 10): 8**

* Completeness and Data Utilization: 9/10 (Most data points were used effectively)
* Accuracy and Clarity: 8/10 (Analysis is clear, but some conclusions are tentative due to limited audited data)
* Professional Formatting: 9/10 (Report is well-structured and easy to read)


**11. Professional Recommendation Summary:**

KIMS shows potential for long-term growth, but the high volatility and reliance on unaudited financial data necessitate a cautious approach.  A "Hold" recommendation is given for the short and medium term, allowing for further evaluation of recent corporate actions and the release of audited financial results.  A "Hold/Consider Buy (with caution)" is suggested for the long term, contingent on positive developments and a more thorough risk assessment.  Investors should closely monitor the company's performance and news releases before making any investment decisions.
